Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS

American Journal of Psychiatry

Volumn 160, Issue 12, 2003, Pages 2231-2233

  Théberge, Jean ^b   Al Semaan, Yousef ^b   Williamson, Peter C ^a   Menon, Ravi S ^b   Neufeld, Richard W J ^b   Rajakumar, Nagalingam ^b   Schaefer, Betsy ^b   Densmore, Maria ^b   Drost, Dick J ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; THALAMUS;

ADULT; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; CHRONIC DISEASE; DOMINANCE, CEREBRAL; FEMALE; GLUTAMIC ACID; GLUTAMINE; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NERVE DEGENERATION; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES; SCHIZOPHRENIA; THALAMUS;

EID: 7244220611     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.12.2231     Document Type: Article

References (14)

1. Olney JW, Farber NB: Glutamate receptor dysfunction in schizophrenia. Arch Gen Psychiatry 1995; 52:998-1007
2. Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158:1367-1377
3. Alexander GE, Crutcher MD, DeLong MR: Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990; 85:119-146
4. 1H spectroscopy at 1.5 and 4.0 Tesla. Magn Reson Med 2000; 44:185-192
5. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, Neufeld RW, Rogers J, Pavlosky W, Schaefer B, Densmore M, Al-Semaan Y, Williamson PC: Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002; 159:1944-1946
6. Bezchlibnyk-Butler KZ, Jeffries JJ (eds): Clinical Handbook of Psychotropic Drugs. Seattle, Hogrefe & Huber, 2002
7. Stanley JA, Drost DJ, Williamson PC, Thompson RT. The use of a priori knowledge to quantify short echo in vivo 1H MR spectra. Magn Reson Med 1995; 34:17-24
8. Rothman DL, Sibson NR, Hyder F, Shen J, Behar KL, Shulman RG: In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Phil Trans R Soc Lond B 1999; 354:1165-1167
9. 1H MRS. Schizophr Res 2001; 49(suppl 1):196
10. Deicken RF, Johnson C, Eliaz Y, Schuff N: Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. Am J Psychiatry 2000; 157:644-647
11. Deicken RF, Zhou L, Schuff N, Weiner MW: Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia. Schizophr Res 1997; 27:65-71
12. 1H-MRS and tissue segmentation. Schizophr Res 2001, 52:87-99
13. Ende G, Braus DF, Walter S, Henn FA: Lower concentration of thalamic N-acetylaspartate in patients with schizophrenia: a replication study. Am J Psychiatry 2001; 158:1314-1316
14. Omori M, Murata T, Kimura H, Koshimoto Y, Kado H, Ishimori Y, Ito H, Wada Y: Thalamic abnormalities in patients with schizophrenia revealed by proton magnetic resonance spectroscopy. Psychiatry Res Neuroimaging 2000; 98:155-162